ROBERT RIFKIN: Open Payments
NPI 1639289051 · SAINT LOUIS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,234 in 64 payments from 15 companies in 2025. Trend: 2023 $3,227 · 2024 $1,677 · 2025 $1,234
Food & beverage: $1,234
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $253 |
| Otsuka America Pharmaceutical, Inc. | 7 | $169 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $151 |
| TMS NeuroHealth Centers Inc. | 1 | $98 |
| Corium, LLC | 4 | $93 |
| Alkermes, Inc. | 4 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $72 |
| Neurocrine BioSciences, Inc. | 4 | $69 |
| Axsome Therapeutics, Inc. | 3 | $48 |
| Noven Therapeutics, LLC | 3 | $47 |
Products named: VRAYLAR, CAPLYTA, REXULTI, TMS NeuroHealth Centers Inc., Azstarys, TRINTELLIX, INGREZZA, ABILIFY MAINTENA.
Industry payments across MO — which companies pay providers there.
